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https://doi.org/10.1016/j.omtn.2019.10.005.Melanoma is a highly aggressive tumor with a poor prognosis,
and half of all melanoma patients harbor BRAF mutations.
A BRAF inhibitor, vemurafenib (PLX4032), has been approved
by the US Food andDrug Administration (FDA) and European
Medicines Agency (EMA) to treat advanced melanoma patients
with BRAFV600E mutation. However, the efﬁcacy of vemurafe-
nib is impeded by adaptive resistance in almost all patients.
In this study, using a cell-based SELEX (systematic evolution
of ligands by exponential enrichment) strategy, we obtained a
DNA aptamer (named LL4) with high afﬁnity and speciﬁcity
against vemurafenib-resistant melanoma cells. Optimized
truncated form (LL4A) speciﬁcally binds to vemurafenib-resis-
tant melanoma cells with dissociation constants in the nano-
molar range and with excellent stability and low toxicity. Mean-
while, ﬂuorescence imaging conﬁrmed that LL4A signiﬁcantly
accumulated in tumors formed by vemurafenib-resistant mela-
noma cells, but not in control tumors formed by their corre-
sponding parental cells in vivo. Further, a transmembrane pro-
tein CD63 was identiﬁed as the binding target of aptamer LL4A
using a pull-down assay combined with the liquid chromatog-
raphy-tandem mass spectrometry (LC-MS/MS) method. CD63
formed a supramolecular complex with TIMP1 and b1-integ-
rin, activated the nuclear factor lB (NF-lB) and mitogen-acti-
vated protein kinase (MAPK) signaling pathways, and contrib-
uted to vemurafenib resistance. Potentially, the aptamer LL4A
may be used diagnostically and therapeutically in humans to
treat targeted vemurafenib-resistant melanoma.7These authors contributed equally to this work.
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Melanoma is a highly aggressive tumor with a poor prognosis in the
metastatic stage. Approximately 50% of melanoma patients harbor a
BRAF mutation, the most common being BRAF(V600E).1 BRAF in-
hibitors, such as vemurafenib (PLX4032) or dabrafenib, were
approved by the US Food and Drug Administration (FDA) and
European Medicines Agency (EMA) to treat advanced melanomaMolecular Thera
This is an open access article under the CC BY-NC-patients with BRAFV600E mutation.2 Unfortunately, nearly 100% of
the patients exhibited drug resistance and disease progression within
6–7 months after treatment with BRAF inhibitors.3,4 Even with cur-
rent development of immune therapy, BRAF-targeted therapy re-
mains an important therapeutic method.5 Developing novel target
treatment methods is still urgently needed.
Aptamers are single-stranded DNA (ssDNA) or RNA molecules that
evolved from random oligonucleotide pools by a process called sys-
tematic evolution of ligands by exponential enrichment (SELEX).6,7
Compared with traditional antibody probes, aptamers have several
advantages, including relatively simple synthesis and modiﬁcation,
low potential for immunogenicity, long-term stability, reversible
denaturation, low toxicity, efﬁcient tissue penetration, and low vari-
ability among different batches.8–10 Because of these advantages, ap-
tamers show great application prospects in drug development, clinical
diagnosis, and targeted therapy.11 Aptamers recognize and bind
speciﬁcally to their targets with high afﬁnity, acting as carriers to
deliver therapeutic agents to their targets, which is the main way
for the potential exploitation of these molecules for diagnosis and
therapy.12–14 Aptamers not only can detect previously known tumor
markers but also can be utilized for discovery of potential novel bio-
markers in human cancers.15 Many aptamers have been used to detectpy: Nucleic Acids Vol. 18 December 2019 ª 2019 The Authors. 727
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Molecular Therapy: Nucleic Acidsa variety of cancers by targeting tumor markers, such as nucleolin,16
tenascin,17 PTK7,18 MUC1,19 c-Met,20 and matrix metalloprotease-9
(MMP-9).21 Therefore, generating a group of aptamers with high
speciﬁcity is an effective and realistic method to discover novel tumor
biomarkers and to construct a targeted delivery system.15
Given the importance of vemurafenib in cancer therapy and its well-
recognized nature of drug resistance, we have developed vemurafe-
nib-resistant melanoma cell lines15 and, for the ﬁrst time, identiﬁed
a group of DNA aptamers that can speciﬁcally recognize the mela-
noma PLX4032-resistant cell lines. One of the selected aptamers,
LL4, and its truncated version aptamer LL4A showed high speciﬁcity
and afﬁnity for resistant cells Mel28-PLX and A375-PLX. Further-
more, in vivo and ex vivo ﬂuorescence imaging demonstrated that
aptamer LL4A could speciﬁcally target the tumors formed by resistant
melanoma cells after intravenous injection into nude mice. Our sub-
sequent studies indicated that LL4A targeted a cell surface protein
CD63, which is a member of the tetraspanin superfamily.
Melanoma patients showed higher plasma levels of CD63 compared
with healthy controls,22 suggesting that CD63 could serve as a poten-
tial biomarker for melanoma. CD63 was known to transmit protein
kinase signals in melanoma cells.23 Recently, CD63 was reported to
be involved in a supramolecular complex with TIMP1 and b1-integ-
rin, conferring melanoma anoikis resistance.24 In breast cancer cells,
CD63 prevented chemo-induced apoptosis, which contributes to
chemoresistance.25 In this study, our results suggest that upregulation
of CD63 in vemurafenib-resistant cells may contribute to cell
survival and vemurafenib resistance by activating the nuclear factor
lB (NF-kB)/TIMP1/CD63/b1-integrin/extracellular signal-regulated
kinase (ERK) pathway. CD63 is a key LL4A binding protein whereby
LL4A could speciﬁcally recognize and bind to melanoma PLX4032-
resistant cell lines.
RESULTS
Selection of the DNA Aptamer LL4 against Mel28-PLX Cells
In a previous study, we generated two PLX4032-resistant melanoma
cell lines, Mel28-PLX and A375-PLX, which were able to proliferate
in the presence of 5 mMPLX4032 and exhibited an IC50 value approx-
imately 20-fold higher than the parental cells Mel28 and A375,
respectively. Meanwhile, RNA sequencing (RNA-seq) and qRT-
PCR arrays data showed that the molecular proﬁles and signaling
pathways have been changed dramatically between PLX4032-resis-
tant cells versus control.26 Therefore, we aimed to obtain a DNA ap-
tamer with high afﬁnity and speciﬁcity against vemurafenib-resistant
melanoma cells, further identify the binding target of the aptamer,
and subsequently investigate the underlying mechanism for vemura-
fenib-induced drug resistance in melanoma cells. To generate ap-
tamers against PLX4032-resistant melanoma cells, Mel28-PLX cells
were used for positive selection, and the parental Mel28 cells were
used for counterselection. The cell-SELEX process is schematically
shown in Figure 1A. The enrichment of the ssDNA library was moni-
tored by ﬂow cytometry during selection. The ﬂuorescence intensity
reﬂected the binding capacity of the enriched pools. As shown in Fig-728 Molecular Therapy: Nucleic Acids Vol. 18 December 2019ure 1B, the ﬂuorescence intensity on target Mel28-PLX cells gradually
increased after incubation with increasing rounds of ﬂuorescein iso-
thiocyanate (FITC)-labeled ssDNA pools. In contrast, almost no in-
crease in ﬂuorescence signal was observed for control cells Mel28
with increasing rounds of incubation (Figure 1C). The target cell-
binding DNA sequences were gradually enriched during the selection
process and ﬁnished after the 15th round of selection. The ﬁnal
ssDNA pool was cloned and subjected to high-throughput
sequencing with Illumina MiSeq.
After sequencing, the aptamer candidates were grouped based on
their sequential repeatability, homogeneity, and the abundance of
each sequence using the MEGA software (Table S1). The six most en-
riched sequences from the six highest conﬁdence groups (six largest
the Bootstrap value) were selected and chemically synthesized for
further research (Table S2). Flow cytometry results demonstrated
that one of these sequences, termed LL4, showed the highest afﬁnity
toward Mel28-PLX cells, in comparison with the control Mel28 cells
(Figure 1D; Figures S1A and S1B). Confocal microscopy imaging was
used to investigate the binding speciﬁcity of aptamer LL4 to Mel28-
PLX cells. After incubation with LL4, the ﬂuorescence signal was
observed mainly on the surface of Mel28-PLX cells, but not on
Mel28 cells (Figure 1E). These results indicated that aptamer LL4
was able to recognize resistant Mel28-PLX cells, but not parental
Mel28 cells. To quantitatively evaluate the binding afﬁnity of LL4 to
Mel28-PLX cells, we measured the equilibrium dissociation constant
(KD). As shown in Figure 1F, the KD of aptamer LL4 for Mel28-PLX
was approximately 101.10 nM, indicating that the selected aptamer
LL4 could speciﬁcally recognize target Mel28-PLX cells with high af-
ﬁnity (a KD of nanomolar level).
Truncation of Aptamer LL4
The full-length aptamer LL4 generated by Cell-SELEX contains 80 nt,
including two ﬂanked primer sequences on each end for PCR ampli-
ﬁcation. However, not all nucleotides of one aptamer are required for
target binding. To reduce the cost of DNA synthesis and further
enhance LL4 speciﬁcity and afﬁnity, the full-length aptamer LL4
was truncated to a minimal functional sequence for further applica-
tions.26 Based on the secondary structure of LL4, predicted by
NUPACK (nucleic acid package) (Figure 2A), seven kinds of trun-
cated sequences from LL4 were synthesized by gradually removing
the nucleotides at the 50 and/or 30 termini (Table S3). Flow cytometry
analysis showed that the truncated LL4A sequence could bind to
Mel28-PLX cells with a higher afﬁnity than other variants or the
full-length aptamer LL4. None of the modiﬁed variants bound to
Mel28 cells (Figures 2B and 2C; Figures S2A and S2B). Quantitative
binding assay showed that aptamer LL4A possessed a KD of
82.18 ± 12.99 nM (Figure 2D).
We also found that aptamer LL4 and its truncated variant LL4A
strongly bind to another PLX4032-resistant melanoma cell line
A375-PLX, but were negative for the parental A375 cells (Figures
S3A and S3B). These results indicate that the LL4A aptamer targeted
speciﬁcally to PLX4032-resistant melanoma cell lines, which suggests
Figure 1. Selection of the DNA Aptamer LL4 against Mel28-PLX Cells
(A) Schematic representation of the cell-SELEX process for PLX4032-resistant melanoma cell Mel28-PLX. (B and C) Flow cytometry assay to monitor the binding of the
selected pool with Mel28-PLX cells (target cells) (B) and Mel28 cells (control cells) (C). The final concentration of the sequences was 250 nM. R, round of selection. (D) Flow
cytometry assays for the binding capacity of LL4 with Mel28-PLX cells. The final concentration of the FITC-labeled sequence was 250 nM. (E) The binding site of FITC-labeled
aptamer LL4 toMel28 andMel28-PLX cells was investigated by confocal microscopy imaging. Scale bars, 25 mm. (F) Determining the binding capacity of LL4withMel28-PLX
cells (dissociation curve for estimating the dissociation constant [KD]).
www.moleculartherapy.orgthat the binding targets of LL4A are perhaps highly expressed in the
resistant cells.
To investigate the LL4A binding site and internalization properties,
PLX4032-resistant melanoma cells (Mel28-PLX and A375-PLX)
and their parental cells (Mel28 and A375) were incubated with
Cy5-labeled LL4A at 4C and 37C for 1 h. Confocal imaging showed
that strong ﬂuorescence was observed on the plasma membrane of
Mel28-PLX and A375-PLX cells after incubation at 4C (Figure 2E;
Figure S4A). However, after incubation at 37C, the ﬂuorescence
signal was mainly located in the cytoplasm of Mel28-PLX and
A375-PLX cells (Figure 2F; Figure S4B). These results suggest that
LL4A could bind to the plasma membrane and rapidly internalize
into Mel28-PLX and A375-PLX cells.
Characterization of LL4A
Cell-SELEX was performed at 4C to avoid enrichment of nonspeciﬁc
DNA sequences caused by endocytosis, which is more active at 37C.
However, selection at 4C may result in poor binding capacity of ap-
tamers at the physiological temperature.27 To investigate whether in-
cubation temperature could affect the binding capacity of LL4A,
Mel28-PLX cells were incubated with LL4A at different temperatures
and then analyzed by ﬂow cytometry. As illustrated in Figure 3A,
Mel28-PLX cells showed similar ﬂuorescence intensity and patterns
after incubation with aptamer LL4A at 4C or 37C, indicating thatthe incubation temperature had little effect on the binding capacity
of LL4A. Moreover, serum stability is usually a concern for the appli-
cation of nucleic acid-based molecules, including DNA and RNA
aptamers. Therefore, we examined the stability of LL4A when incu-
bated with Minimum Essential Medium (MEM) supplemented with
10% human serum. During the incubation with human serum,
LL4A was stable with up to 8 h of incubation at 37C, showing no
signs of degradation. LL4A started to degrade after 12 h, but a signif-
icant portion remained even after 36 h (Figure 3B). Moreover, LL4A
also showed a good serum stability in mouse serum and fetal bovine
serum (FBS) at 37C (Figure S5). In addition, toxicity is also a key
limiting factor in the clinical application of aptamers. As shown in
Figure 3C, MTT results demonstrated that after incubation with
10 mM LL4A for 48 h, Mel28, Mel28-PLX, and human normal kera-
tinocyte HaCaT cells showed no signiﬁcant survival rate change, indi-
cating that aptamer LL4A has no in vitro toxicity. Given the above re-
sults, the DNA aptamer LL4A is stable enough for subsequent in vivo
studies and also will be useful for future clinical applications.
In Vivo and Ex Vivo Xenograft Fluorescence Imaging
To test whether aptamer LL4A retained its recognition ability in vivo,
a systematic comparative investigation28 was performed to validate
the selectivity of Cy5-labeled LL4A in the same mouse model, in
which Mel28 and Mel28-PLX cells were implanted on the left and
right sides of the back, respectively (Figure 4A). Imaging studiesMolecular Therapy: Nucleic Acids Vol. 18 December 2019 729
Figure 2. Truncation of Aptamer LL4 and
Characterization of LL4A
(A) Secondary structure of LL4 predicted by NUPACK. (B)
Binding ability of different truncated versions of LL4
generated by removing nucleotides at the 50 and 30 termini
(250 nM) on target Mel28-PLX cells. (C) Flow cytometry
assays for the binding capacity of LL4 and LL4A (250 nM)
to Mel28-PLX cells. (D) Dissociation constant (KD) curve of
LL4A for Mel28-PLX cells. (E and F) The binding site (E)
and the internalization (F) of Cy5-labeled aptamer LL4A to
Mel28 andMel28-PLX cells at 4Cand 37C, respectively,
were investigated by confocal microscopy imaging. Scale
bars, 25 mm.
Molecular Therapy: Nucleic Acidsshowed that after injecting Cy5-labeled LL4A through the tail vein,
aptamer LL4A speciﬁcally targeted and accumulated in tumors
formed by Mel28-PLX cells, but not in tumors formed by control
Mel28 cells in the same mouse. A ﬂuorescent signal was also observed
in kidney tissue, which suggested that LL4A was excreted and cleared
by the kidneys. The speciﬁc imaging signal lasted up to 120 min post
systemic administration (Figure 4B). Aptamer LL4A also presented
more ﬂuorescence signal accumulation in excised Mel28-PLX tumors
than in Mel28 tumors (Figure 4C). These results demonstrated that
aptamer LL4A was able to recognize and target to the PLX4032-resis-
tant melanoma cells in vivo, which established a base for future use as
a molecular probe for prognosis, especially use in monitoring devel-
opment of PLX4032 resistance during treatment.
CD63 Is the Binding Target of Aptamer LL4A
Next, in order to discover the mechanism of aptamer LL4A, we iden-
tiﬁed its potential targets that could be proteins, lipids, saccharides or
other organic molecules.29 After Mel28-PLX cells were incubated
with trypsin or Proteinase K, aptamer LL4A completely lost its bind-
ing capacity (Figure 5A), suggesting that the target of LL4A was a
membrane protein. Based on this ﬁnding, we incubated biotin-tagged
LL4A with solubilized membrane protein from Mel28-PLX cells, and
streptavidin-coated magnetic beads were used to extract biotin-
labeled LL4A binding complexes (the initial ssDNA library was
used as control). The beads along with the capture proteins were
then eluted and separated by SDS-PAGE (Figure 5B). Compared730 Molecular Therapy: Nucleic Acids Vol. 18 December 2019with control experiments, the characteristic pro-
tein bands (50 kDa) on the gel captured by
biotin-labeled LL4A were digested and sub-
jected to liquid chromatography-tandem mass
spectrometry (LC-MS/MS) QSTAR analysis. A
MASCOT database search was used to assign
possible protein candidates to the MS results
(Table S4). Interestingly, CD63 is highly en-
riched among the surface transmembrane pro-
tein candidates (Figure S6).
To validate that LL4A binds to CD63, ﬁrst an
aptamer-mediated pull-down assay was per-
formed in A375-PLX cells. As shown in Fig-ure 5C, biotin-labeled LL4A, but not Library-captured proteins, could
bind to CD63 antibody, indicating a direct interaction between LL4A
and CD63. Subsequently, an immunoﬂuorescence experiment was
used to examine the co-localization between LL4A and CD63 on
the Mel28-PLX cells (Figure 5D). CD63 showed both plasma mem-
brane and cytoplasmic locations as found in other cells reported
before.30 LL4A showed complete overlapping signal with CD63 on
the plasma membrane of Mel28-PLX cells (Figure 5D). We next
used the small interfering RNA (siRNA) to knock down CD63 in
Mel28-PLX cells, with random siRNA as negative control (Figure 5E).
These cells were analyzed with ﬂow cytometry after incubation with
LL4A; the results showed a dramatic reduction of LL4A ﬂuorescence
in the CD63 knocked down Mel28-PLX cells in a siRNA concentra-
tion-dependent manner as compared with the negative control cells
(Figure 5F). Conversely, overexpression of CD63 in A375-PLX cells
(where CD63 was at a lower level than in Mel28-PLX cells) dramat-
ically increased the binding afﬁnity of LL4A to A375-PLX cells (Fig-
ures 5G and 5H), indicating that CD63 is an important LL4A binding
protein on the Mel28-PLX and A375-PLX cells. To investigate
whether LL4A shares the same binding site with anti-CD63 antibody
to multiple transmembrane protein CD63, we performed a competi-
tion assay by ﬂow cytometry. Cy5-labeled LL4A and FITC-labeled
anti-CD63 antibody were co-incubated with Mel28-PLX cells, and
ﬂow cytometry results showed few changes in the binding of LL4A
to Mel28-PLX cells; also, LL4A had no obvious inﬂuence on anti-
CD63 antibody binding (Figure S7), indicating that the different sites
Figure 3. Characterization of LL4A
(A) Flow cytometry assays for the binding capacity of LL4A to Mel28-PLX cells at 4C or 37C, respectively. (B) Aptamer LL4A was incubated in human serum, and its
biostability was evaluated by gel electrophoresis of the residual products at the indicated time points. (C) The in vitro toxicity of LL4A in Mel28, Mel28-PLX, and HaCaT cells
was investigated by MTT assay.
www.moleculartherapy.orgof the extracellular domain of CD63 were simultaneously bound
by LL4A and antibody. Finally, the binding afﬁnity by enzyme-
linked oligonucleotide assay (ELONA) revealed that the KD of
LL4A against puriﬁed His-CD63 was 84.63 ± 13.04 nM (Figure 5I).
Taken together, we identiﬁed that CD63 was the binding target of
aptamer LL4A.
CD63 Contributes to PLX4032 Drug Resistance in Melanoma
Cells
Previous studies indicated that TIMP1 bound to the tetraspanin
membrane receptor CD63 and assembled a supramolecular com-
plex with b1-integrin, further triggering the hyperactivation of
NF-kB and phosphorylation of ERK1/2, and eventually leading
to promotion of cell growth and invasion.31,32 In this study, we
found that PLX4032 resistance cells formed a TIMP1/CD63/b1-in-
tegrin supramolecular complex through co-localization ﬂuorescent
assay and co-immunoprecipitation assay (Figure S8). Therefore, we
next examined the role of CD63 in the NF-kB and mitogen-acti-
vated protein kinase (MAPK) pathway, and its impact in response
to PLX4032. As shown in Figure 6A, we observed the elevated
expression of the TIMP1/CD63/b1-integrin axis and activated
NF-kB and ERK signaling pathways in both PLX4032-resistant
melanoma cells (Mel28-PLX and A375-PLX), as compared with
the parental cells (Mel28 and A375). Furthermore, the PLX4032-
resistant cells also showed enhanced b1-integrin-mediated
signaling, perhaps through TIMP1/CD63, but not PI3K/AKT,
signaling pathways, because there was no difference in p-AKT
levels between PLX4032-resistant melanoma cells and their
parental cells. To further determine whether the elevated NF-kB/
TIMP1/CD63/b1-integrin/ERK pathway was involved in
PLX4032 resistance in melanoma cells, CD63 was knocked down
in Mel28-PLX cells, and a signiﬁcant reduction in TIMP1 expres-
sion and ERK1/2 phosphorylation was observed as compared with
the control cells treated with negative control siRNA (siNC) (Fig-
ure 6B). Furthermore, when CD63 was knocked down, Mel28-PLX
and A375-PLX cells were much more sensitive to PLX4032 treat-
ment (Figures 6C and 6D). Taken together, our results suggest
that the elevated expression of the TIMP1/CD63/b1-integrin axismediates the activation of the NF-kB and ERK1/2 signaling path-
ways, contributing to PLX4032 resistance, but this regulation is in-
dependent of AKT phosphorylation.
DISCUSSION
In this study, using the cell-based SELEX strategy, we discovered a
DNA aptamer LL4 and its truncated form LL4A, which could bind
to vemurafenib-resistant melanoma cells with high afﬁnity, both
in vitro and in vivo. Furthermore, we characterized LL4A to be highly
stable under physiological conditions with super-low toxicity. We
further identiﬁed CD63 as the cell surface target for LL4/LL4A and
explored the role of CD63 in vemurafenib resistance. These ﬁndings
paved the way to develop aptamers LL4/LL4A in versatile biomedical
applications such as bioimaging and targeted therapy, and suggested a
new mechanism for vemurafenib-induced drug resistance in mela-
noma cells.
A potential use of LL4/LL4A is in imaging for patient prognosis
monitoring during vemurafenib treatment by optical bioimaging,
positron emission tomography (PET), single-photon emission
computed tomography (SPECT), or magnetic resonance imaging
(MRI) using the modiﬁed aptamers with ﬂuorescent dyes, radioiso-
topes, or magnetic nanomaterial reporters. This will help doctors
to make early decisions of switching patients to other treatments.
A second potential use of these aptamers is to be developed as
therapeutic agents in the form of aptamer-drug conjugates
(ApDCs). Because aptamer LL4A itself is not toxic to melanoma
cells and human normal keratinocytes, it can be internalized into
vemurafenib-resistant cells. This opens the therapeutic windows
for LL4A as targeting ligands for drug delivery in the form of
ApDCs. The ApDC-mediated chemotherapy could speciﬁcally
deliver drugs to diseased tissues or cells, and thus reduce side
effects and improve therapeutic efﬁcacy.33 In addition, ApDC
could be used in mediating gene therapy. Speciﬁcally, aptamers
can be conjugated with nucleic acid gene therapeutics, ranging
from siRNA, small hairpin RNA (shRNA), and microRNA
(miRNA) by molecular engineering of nucleic acids, which reduces
the potential “off-target” effect in gene delivery.33Molecular Therapy: Nucleic Acids Vol. 18 December 2019 731
Figure 4. In Vivo and Ex Vivo Xenograft Fluorescence Imaging
(A) The animal model bearing both a Mel28 tumor (left) and a Mel28-PLX tumor
(right) will be systemically administered with Cy5-labeled aptamer LL4A through the
tail veins. (B) The two sides of tumor-bearing mice were intravenously injected with
Cy5-labeled aptamer LL4A and then imaged at the indicated time points. (C) The
excised Mel28 tumor (left) and Mel28-PLX tumor (right) tissues were harvested, and
the fluorescence signals of tumor tissues were collected by using the IVIS Lumina II
in vivo imaging system.
Molecular Therapy: Nucleic AcidsA third potential application of LL4/LL4A aptamers is for discov-
ery of biomarkers. The cell-SELEX process is simple, fast, and
reproducible, and can be done without prior knowledge of target
molecules. The selected aptamers can speciﬁcally recognize target
cancer cells mixed with normal cells.34 In this study, we used ap-
tamer-mediated pull-down assay combined with LC-MS/MS
QSTAR analysis and identiﬁed CD63 as a potential biomarker
for vemurafenib resistance. CD63 was an abundant surface antigen
in early-stage human melanoma cells.35 TIMP1 is a CD63 ligand,
and CD63 acts as a regulator of the PI3K, FAK, Src, and Akt
signaling pathways. CD63-mediated signaling is implicated in the
anti-apoptotic activity of TIMP1.36 The interaction of CD63 and
TIMP1 is also involved in survival and increased chemoresistance
in different human cancers, which may be mediated by hyperacti-
vation of NF-kB and phosphorylation of ERK1/2.25,37,38 In mela-
noma, the BRAFV600E mutation is associated with the hyper-activa-
tion of NF-kB and upregulation of both TIMP1 and its receptor
CD63.31 Here, we show evidence that elevated NF-kB/TIMP1/
CD63/b1-integrin axis facilitates melanoma drug resistance
through activation of NF-kB and ERK1/2 signaling pathways
without AKT phosphorylation. Our results appear contradictory
with a recent study by Kudo et al.,39 which reported that CD63
was able to sensitize melanoma cell lines to PLX4032. These
seeming conﬂicts may be caused by several factors, including
different drug selection method for resistant cells, leading to differ-
ences in the genetic background of resistant cell lines, cell hetero-
geneity during the course of drug screening, and measurement
method of drug resistance. In fact, CD63 was found to be one of
the best genes that could efﬁciently distinguish BRAF mutant732 Molecular Therapy: Nucleic Acids Vol. 18 December 2019versus BRAF-wild-type melanomas, and the correlation between
V600E mutation and CD63 overexpression was extremely strong
in the melanoma.40 In addition, our results are consistent with
another previous study that described an increased level of
CD63-Timp1-b1-integrin supramolecular complex along mela-
noma progression.24 More work is warranted in fully character-
izing the role of CD63-related signaling in melanoma progression
and drug resistance.
Furthermore, CD63 abundantly localizes at extracellular vesicle
exosomes released from melanoma cells. Logozzi et al.22 found
that plasma exosomes expressing CD63 were signiﬁcantly
increased in melanoma patients compared with healthy donors.
Since then, CD63 is commonly used as an exosome marker for
melanoma. Exosomes have been shown to promote tumor develop-
ment, such as metastatic niche formation, tumor immune escape,
and drug resistance.41 Peinado et al.42 reported that exosomes
derived from melanoma cells enhanced metastasis through educa-
tion of bone marrow-derived cells in order to prime the pre-met-
astatic niche and increase vascularization, indicating that exosomal
CD63 may be a potential therapeutic target for melanoma. Indeed,
Nishida-Aoki et al.43 demonstrated that treatment with human-
speciﬁc anti-CD63 antibodies signiﬁcantly suppressed tumor
metastasis in a human breast cancer xenograft mouse model. In
particular, anti-CD63 antibody-tagged cancer-derived exosomes
were preferentially internalized and eventually eliminated by mac-
rophages.43 Similar to antibodies, aptamers bind to their targets
with high afﬁnity and selectivity. However, aptamers are advanta-
geous over antibodies in terms of their low potential for immuno-
genicity, efﬁcient tissue penetration, and relatively simple synthe-
sis. Based on the LL4A antigenic, biological, and molecular
properties, LL4A could be developed as a promising molecular
tool for targeting applications in melanoma, such as target identi-
ﬁcation of Plx4032-resistant cells, targeting killing resistant cells
via loading with chemotherapy drugs, targeting labeling, and isola-
tion of plasma exosomes expressing CD63. Furthermore, devel-
oping a bi-speciﬁc/bivalent aptamer that targets both CD63 and
co-inhibitory molecules, like PD-L1, CTLA-4, and B7-H4, may
enhance tumor-immune interactions.
Taken together, this study identiﬁed a novel aptamer, LL4A, which
could serve as a potential imaging probe for prognosis or as a carrier
for targeted therapeutics against PLX4032-resistant melanoma with
high expression of CD63. Our results suggest future therapy methods
can be developed based on blocking CD63 by antibodies or small-
molecule inhibitors, or using LL4A as a CD63 siRNA delivery tool
for developing novel combination therapy with vemurafenib.
MATERIALS AND METHODS
Cell Culture and Reagents
Human malignant melanoma cells SK-Mel28 (Mel28), A375, and hu-
man normal keratinocyte HaCaT were purchased from the ATCC.
Mel28-PLX and A375-PLX (PLX4032-resistant Mel28 and A375
parental) cells were obtained and cultured as described in a previous
Figure 5. CD63 Is the Binding Target of Aptamer LL4A
(A) Binding capacity of LL4A toMel28-PLX cells pretreatment Proteinase K or trypsin wasmeasured by flow cytometry. (B) Colloidal silver-stained SDS-PAGE used to analyze
the LL4A-assisted target purification. (C) The direct interaction between LL4A and CD63 in Mel28-PLX cells was detected using an aptamer pull-down assay, and the CD63
protein was examined by western blotting. (D) The co-localization of Cy5-labeled LL4A and anti-CD63 in Mel28-PLX cells was investigated by confocal microscopy imaging.
Top panels: scale bars, 25 mm; bottom panels: scale bars, 10 mm. (E) The knockdown efficiency of CD63 was determined by western blotting. (F) Binding capacity of LL4A in
CD63 knockdown Mel28-PLX cells and control cells was measured by flow cytometry. (G) The overexpression efficiency of CD63 in A375-PLX cells was determined by
western blotting. (H) Binding capacity of LL4A in CD63 overexpressed A375-PLX cells and control cells wasmeasured by flow cytometry. (I) Dissociation constant of LL4A for
purified His-CD63 recombinant protein was determined by ELONA.
www.moleculartherapy.orgstudy.26 The cells were incubated in a humid atmosphere maintained
at 37C with 5% CO2. Mel28/Mel28-PLX and A375/A375-PLX cells
were cultured in MEM (HyClone, USA) and DMEM (HyClone,
USA), respectively, supplemented with 10% FBS (GIBCO, USA),
100 U/mL penicillin, and 100 mg/mL streptomycin (Life Technolo-
gies, USA). Mel28-PLX and A375-PLX were generated by prolonged
cell culture in the presence of PLX4032. PLX4032 was purchased
from Selleck Chemicals (Houston, TX, USA) and dissolved in
DMSO at a concentration of 5 mM. For each cell passage cultivation,
the ﬁnal concentration of PLX4032 (5 mM) was freshly prepared in
MEM. SELEX washing buffer for aptamers was prepared with Dul-
becco’s PBS (DPBS; Thermo Fisher Scientiﬁc) supplemented with
4.5 mg/mL glucose (Sigma, Germany) and 5 mMMgCl2 (Sigma, Ger-
many). SELEX binding buffer for aptamers was prepared by adding
0.1 mg/mL yeast tRNA (Sigma, Germany) and 1 mg/mL BSA (Sigma)
into the washing buffer to diminish background binding.DNA Library and Primers
The DNA library used in the cell-SELEX was constructed from oligo-
nucleotide sequences with a length of 80 nt based on the following
generic sequence: 50-ACCGACCGTGCTGGACTCA(N)42
ACTATGAGCGAGCCTGGCG-30. The speciﬁc oligonucleotide
sequence contained a 19-nt ﬁxed sequence on both sides and the mid-
dle 42-nt randomized region, where N represents a randomized
nucleotide (A, T, G, or C). A FITC-labeled forward primer (50-FITC-
ACCGACCGTGCTGGACTCA-30) and a biotin-labeled reverse
primer (50-biotin-CGCCAGGCTCGCTCATAGT-30) were used in
the PCR ampliﬁcation for the synthesis of double-labeled, dou-
ble-stranded DNA (dsDNA) sequences. The DNA library and
primers used in the cell-SELEX were synthesized and high-pres-
sure liquid chromatography (HPLC) puriﬁed by Sangon Biotech
(Shanghai, China).Molecular Therapy: Nucleic Acids Vol. 18 December 2019 733
Figure 6. CD63 Contributes to PLX4032 Drug
Resistance in Melanoma Cells
(A) Western blotting analysis of the expression of CD63,
TIMP1, b1-integrin, NF-kB, ERK, and PI3K/AKT
signaling pathways in Mel28/Mel28-PLX and A375/
A375-PLX cells. GAPDH served as a loading control. (B)
Mel28-PLX cells were knocked down with siCD63-1,
siCD63-2, and siNC for 48 h, and the CD63, TIMP1,
b1-integrin, NF-kB, ERK, and PI3K/AKT signaling
pathways were analyzed by western blotting. (C and D)
Mel28-PLX (C) and A375-PLX (D) cell viability as
measured by the MTT assay after the cells were
transfected with either siCD63 or siNC for 48 h.
Molecular Therapy: Nucleic AcidsCell-SELEX Procedures
The cell-SELEX process was performed using Mel28-PLX cells as the
target cells and Mel28 cells as the negative control cells, as reported
previously with a fewmodiﬁcations.44 For the ﬁrst and second rounds
of SELEX, the initial library pool (10 OD/optical density) was incu-
bated with Mel28-PLX cells at 4C for positive selection. After incu-
bation, the supernatant solution was discarded, and the cells were
washed to remove unbound sequences. Then Mel28-PLX cells were
collected, and the cell-bound ssDNA was harvested by heating the
cell-DNA complexes. The harvested cell binding ssDNA was used
as a template for PCR ampliﬁcation, and the dsDNA product was
separated from the PCR solution by streptavidin-coated Sepharose
beads (GE Healthcare, USA) and then treated with 0.2 M NaOH, fol-
lowed by desalting with NAP-5 column (GE Healthcare, USA) to
obtain the FITC-labeled ssDNA. Finally, after lyophilization, the
FITC-labeled ssDNA pool was used for the next round of selection.
Starting from the third round of selection, the negative control Mel28
cells were ﬁrst incubated with the selected ssDNA pool evolved from
the last round for negative selection. The unbound ssDNAs were then
removed and applied onto Mel28-PLX cells to enrich the speciﬁc
binders to the target. As the number of selection rounds increased,
the negative incubation time was increased from 30 min to 2 h,
whereas the positive incubation time was gradually shortened from
2 h to 30 min to increase the stringency and accuracy of the selection.
Additionally, the washing times gradually increased from two to three
times, and the amount of the ssDNA library used for subsequent
rounds of selection was decreased gradually. The enrichment of the
selected FITC-labeled ssDNA pools was monitored by detecting the
FITC ﬂuorescence signal with ﬂow cytometry (BD FACSCalibur
ﬂow cytometer, USA). Following 15 rounds of selection, the ﬁnal
ssDNA pool was subjected to high-throughput sequencing using Illu-
mina MiSeq by Sangon Biotech (Shanghai, China).
Flow Cytometric Analysis
Target and negative cells were cultured in 100-mm-diameter culture
dishes to 80%–90% conﬂuence. Both cell lines were washed twice
with 2 mL of DPBS, followed by digestion with 1 mL of 0.02%734 Molecular Therapy: Nucleic Acids Vol. 18 December 2019EDTA. Then 2  105 Mel28/Mel28-PLX cells and A375/A375-PLX
cells were respectively incubated with 250 nM FITC-labeled selected
ssDNA pools and the initial library in 400 mL of binding buffer at
4C for 1 h in the dark place to monitor the enrichment of the evolved
ssDNA pools. In the same way, each cell line (2 105) was incubated
with aptamer or initial library to analyze the binding speciﬁcity of
the aptamer. The FITC-labeled ssDNA library was used as a negative
control to distinguish nonspeciﬁc binding from speciﬁc binding. After
incubation, each cell sample was washed twice with 500 mL of washing
buffer, re-suspended in 400 mL of binding buffer, and then analyzed
with a BD FACSCalibur ﬂow cytometer. All experiments for the bind-
ing speciﬁcity assay were repeated three times independently.
Aptamer Truncation
The nucleotide secondary structure of aptamer LL4 was predicted by
using the bioinformatics software NUPACK. Seven truncated se-
quences were synthesized by gradually removing the nucleotides at
the 50 and 30 termini based on the secondary structure analysis of
LL4 and then performing a binding assay. All experiments were
repeated three times independently.
Affinity Analysis
To quantitatively assess the afﬁnity of aptamer to target Mel28-
PLX cells, we measured the equilibrium KD of aptamers by Graph-
Pad software. Target Mel28-PLX cells (2  105) were incubated
with increasing concentrations of FITC-labeled aptamers and the
initial library in 400 mL of binding buffer at 4C for 1 h in the
dark and then analyzed by ﬂow cytometry. The FITC-labeled initial
library was used as a negative control. The KD of the aptamers on
Mel28-PLX cells was determined by measuring the dependence of
the ﬂuorescence intensity of aptamers by different aptamer con-
centrations with the equation Y = Bmax X/(KD+X). All experi-
ments for the binding afﬁnity assay were repeated three times inde-
pendently, and data are expressed as means ± SEM.
Aptamer Internalization Analysis
A total of 1  105 Mel28/Mel28-PLX cells and A375/A375-PLX cells
were respectively incubated with 250 nM Cy5-labeled aptamer at
www.moleculartherapy.org37C for 1 h in the dark. After incubation, the cells were washed twice
with washing buffer, ﬁxed with 4% paraformaldehyde for 10 min, and
then stained with 400 mL of DAPI for 5 min. The images were
captured by a Leica SP5 II scanning confocal microscope (Leica, Ban-
nockburn, IL, USA). All experiments were performed in triplicate,
and data shown in the ﬁgures are representative of all of the experi-
mental replicates.
Trypsin and Proteinase K Dissociating Analysis
Target Mel28-PLX cells were washed twice with 2 mL of DPBS and
then dissociated with 200 mL of 0.02% EDTA, 0.25% trypsin, or
0.2 mg/mL Proteinase K for 10 min at room temperature. After add-
ing complete culture medium to inhibit proteinase activity, the cells
were washed and then incubated with FITC-labeled aptamer
(250 nM) in 400 mL of binding buffer at 4C for 40 min in the
dark. After washing, all cell samples were analyzed by ﬂow cytometry
as described in the previous section. All experiments were performed
in triplicate, and data shown in the ﬁgures are representative of all the
experimental replicates.
Effects of Temperature on Aptamer Binding
To investigate whether the temperature will affect the binding ability
of aptamers, target Mel28-PLX cells were dissociated with 0.02%
EDTA and incubated with FITC-labeled aptamer (250 nM) in
400 mL of binding buffer for 1 h in the dark placed at 4C or 37C,
respectively. The binding afﬁnity was measured by ﬂow cytometry.
All experiments were performed in triplicate, and data shown in
the ﬁgures are representative of all of the experimental replicates.
Aptamer Biostability Assays
Next, 3 mM FITC-labeled aptamer was incubated in 400 mL of MEM
supplemented with 10% human serum, mouse serum, or FBS at 37C
at the indicated time points. After incubation, 40 mL of sample was
collected for each time point and denatured immediately at 95C
for 10 min, followed by storage at 80C. After ﬁnishing the collec-
tion, the samples were thawed at 4C and then subjected to electro-
phoretic separation on a 3% agarose gel. The amount of undigested
aptamer was visualized and further analyzed by a molecular imager
(Bio-Rad Laboratories, China). Each bar represents the mean ±
SEM of three independent experiments.
In Vivo Fluorescence Imaging
All animal procedures were approved by the Animal Care and Use
Committee of the Third Xiangya Hospital of Central South University
(Changsha, Hunan, China) and performed strictly in accordance with
institutional policies and approved guidelines of experiment opera-
tions. The in vivo ﬂuorescence imaging assay was performed as
reported previously28 with a few modiﬁcations. In detail, 4- to 6-
week-old female athymic BALB/c (BALB/c-nude) mice were pur-
chased from Hunan SJA Laboratory Animal. Then, 4  106 Mel28
cells and Mel28-PLX cells were co-implanted subcutaneously in the
opposite ﬂanks of BALB/c-nude mice. When the tumors reached
0.5–1.0 cm3, tumor-bearing BALB/c nude mice were anesthetized
and then injected intravenously with 6.5 nM Cy5-labeled aptamerdissolved in DPBS via the tail vein. At the indicated time points,
the ﬂuorescence signal was monitored on an IVIS Lumina II in vivo
imaging system (Caliper Life Sciences, USA). For the in vitro ﬂuores-
cence experiment, tumor-bearing BALB/c nude mice were intrave-
nously injected with Cy5-labeled aptamer via the tail vein. Then the
mice were anesthetized and euthanized by cervical dislocation 1 h af-
ter injection. The excised Mel28-PLX and Mel28 tumor tissues were
harvested, and the ﬂuorescence signals of tumor tissues were collected
by using the IVIS Lumina II in vivo imaging system. All experiments
were performed in triplicate, and data shown in the ﬁgures are repre-
sentative of all of the experimental replicates.
Aptamer-Mediated Pull-Down Assay
A total of 5  106 Mel28-PLX or A375-PLX cells were washed three
times with precooling DPBS and lysed in 5 mL of hypotonic buffer
(washing buffer containing 10 cocktail, 1 M Tris-HCl, and 100
PMSF) at 4C for 30 min. After centrifugation, the debris was washed
three times with 5 mL of hypotonic buffer and dissolved in 2 mL of
lysis buffer (hypotonic buffer containing 1% Triton X-100) at 4C
for 30 min. After centrifugation, the supernatant was collected and
then incubated with 150 pmol nonbinding biotin-labeled library se-
quences for 1 h at 4C as a nonspeciﬁc competitor. The protein-
DNA complex was captured by incubating it with 2 mg (200 mL) of
streptavidin-coated magnetic beads for 1 h at 4C and collecting
the beads on a magnetic stand. After centrifugation, the resulting
supernatant was incubated with 150 pmol biotin-labeled LL4A for
1 h at 4C, and the protein-LL4A complex was captured by incubating
it with 2 mg (200 mL) of streptavidin-coated magnetic beads at 4C
for 1 h and then collecting the beads on a magnetic stand. The
collected magnetic beads were washed ﬁve times with 1 mL of SELEX
washing buffer. The beads along with the captured proteins were
eluted by heating in 30 mL of loading buffer and then separated by
PAGE (12%, SDS-PAGE), followed by staining with colloidal silver
or immunoblotting with speciﬁc CD63 antibody. The aptamer-puri-
ﬁed protein bands were digested and subjected to LC-MS/MS QStar
analysis. A MASCOT database search was used to assign possible
protein candidates to the MS results. All experiments were performed
in triplicate, and data shown in the ﬁgures are representative of all of
the experimental replicates.
Confocal Microscopy Imaging
For confocal imaging of the aptamers bound with the cells, 1  105
Mel28/Mel28-PLX cells and A375/A375-PLX cells were respectively
seeded onto glass coverslips in 24-well dishes and cultured for 24 h.
After washing twice with cold washing buffer, the cells were incubated
with FITC/Cy5-labeled aptamer (250 nM) in 400 mL of binding buffer
at 4C for 1 h in the dark. Subsequently, the cells were washed twice,
ﬁxed with 4% paraformaldehyde for 10 min, and then stained with
400 mL of DAPI for 5 min. The images were captured by a Leica
SP5 II scanning confocal microscope (Leica, Bannockburn, IL, USA).
For confocal imaging of the co-localization of the LL4A aptamer
and the anti-CD63 antibody, Mel28-PLX cells were directly labeled
with Cy5-LL4A and then incubated with anti-CD63 monoclonalMolecular Therapy: Nucleic Acids Vol. 18 December 2019 735
Molecular Therapy: Nucleic Acidsantibodies at a 1:100 dilution for 2 h at 37C. The cells were then incu-
bated with a 1:100 dilution of TRITC (Tetramethylrhodamine-5-
(and-6)-isothiocyanate)-conjugated goat anti-mouse immunoglob-
ulin G (IgG; Jackson ImmunoResearch Laboratories) for 1 h at
37C in the dark. The images were captured using a Leica SP5 II scan-
ning confocal microscope (Leica, Bannockburn, IL, USA).
ELONA
Experimental protocols were conducted according to a previous
description.45 In brief, His-CD63 recombinant protein (11271-H08H;
Sino Biological, China) was diluted to 1 mg/mL with binding buffer,
and 200 mL of the solution was added to a 96-well microtiter plate
(NUNC, Rochester, NY, USA) and then incubated overnight at 4C.
Then thewellswerewashed four timeswithwashing buffer and blocked
with 1% BSA in PBS for 2 h at 37C and then washed three times with
washing buffer. Afterward, biotin-labeled aptamer LL4A or Library
(Sangon Biotech, China) was denatured for 10 min at 95C and cooled
for 10min on ice, then diluted in binding buffer at concentrations indi-
cated in the ﬁgures. Next, 200 mL of the solution was added to eachwell,
and the plate was incubated at 37C for 1 h and then washed four times
withwashing buffer to remove unbound ssDNA.Afterward, 200mL of a
1:2,000 dilution of streptavidin labeled with horseradish peroxidase
(D3308; Beyotime, China) was added to each well, and then the plate
was incubated at room temperature for 2 h. At last, the plate waswashed
four times and developed by EL-ABTS Chromogenic Reagent kit
(C510031; SangonBiotech,China), and then405-nmsingle-wavelength
absorbance was detected by using a microplate reader.
Western Blotting
Experimental protocols were conducted according to our previous
description.46 In brief, the cells were lysed with radioimmunoprecipi-
tation assay (RIPA) buffer containing a protease or phosphatase
inhibitor mixture; 25 mg of proteins was separated by SDS-PAGE, fol-
lowed by immunoblotting with speciﬁc antibodies (Table S5).
Co-immunoprecipitation
For endogenous co-immunoprecipitation assays, cells were lysed in
cold IP (immunoprecipitation) buffer (P0013; Beyotime, China) sup-
plemented with protease inhibitor cocktail (Roche, France), 5%–10%
of the cell extract was saved as the input, and the rest was incubated
with primary antibody at 4C overnight and then with protein A/G
agarose beads (Santa Cruz, USA) for 2 h at 4C. After washing three
times with the IP buffer, bound proteins were eluted by boiling with
2 SDS loading buffer and then separated by PAGE (10%, SDS-
PAGE), followed by immunoblotting with speciﬁc antibody (Table S5).
Small Interfering RNAi and Transfection
siRNAs targeting CD63 and an unrelated sequence as a negative con-
trol were synthesized by GenePharma (Shanghai, China), and the se-
quences of the siRNAs are listed in Table S6. CD63 overexpression
plasmid and null vector were purchased from Sino Biological (Beijing,
China). Mel28-PLX cells were transfected with CD63 siRNA or over-
expressed plasmid using the riboFECTTM CP Transfection Kit (Ri-
boBio, Guangzhou, China) according to the manufacturer’s protocol.736 Molecular Therapy: Nucleic Acids Vol. 18 December 2019The knockdown efﬁciency was measured by western blotting. The
binding ability of LL4A to Mel28-PLX cells transfected with CD63
siRNAs was assessed by ﬂow cytometric analysis.
Competition Assay of Aptamer and Antibody
A total of 250 nM Cy5-labeled LL4A and FITC-labeled anti-CD63
antibody was prepared and incubated alone or co-incubated with
the Mel28-PLX cells in 200 mL of binding buffer at 4C for 1 h. After
incubation, non-bound aptamers or antibody was washed out, and
then cells were resuspended in 500 mL of binding buffer. Flow cytom-
eter was used to measure the ﬂuorescence intensity of each sample.
MTT Assay
The cells were seeded into ﬂat-bottom 96-well plates (3  103 cells/
well) and grown for 24, 48, and 72 h. At each time point, 20 mL of
MTT working solution was added to the medium and incubated for
4 h. Subsequently, the medium was removed, and 200 mL of DMSO
was added to dissolve the formazan crystals. The absorbance at
570 nm (A570) was read on a microplate reader (Bio-Rad, Hercules,
CA, USA). All experiments were performed in triplicate, and data are
expressed as means ± SEM.
Statistical Analyses
All statistical analyses were performed using SPSS 16.0 statistical soft-
ware. Student’s t test was used to determine the signiﬁcance of the dif-
ferences between the control and the experimental groups. A p value
<0.05 was considered statistically signiﬁcant.
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